urabrelimab (SRF231)

News alerts, weekly reports and conference planners

Company:

Coherus Biosci

Drug class:

CD47 inhibitor

Related drugs:

‹

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D
EGFR H1975	Non Small Cell Lung Cancer	EGFR H1975	Non Small Cell Lung Cancer	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D	SRF231 Sensitive: D – Preclinical SRF231 Sensitive : D

Associations
(2)